Cryptococcal meningitis
The most important markers of poor prognosis in HIV-associated cryptococcal meningitis are altered mental status at presentation and high organism load, as determined by quantitative cerebrospinal fluid (CSF) culture or CSF antigen titre.[91]Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004 May 29;363(9423):1764-7.
http://www.ncbi.nlm.nih.gov/pubmed/15172774?tool=bestpractice.com
Low CSF white cell count and raised CSF opening pressure are also associated with a poor outcome. Mortality in non-HIV-associated cryptococcal meningitis is associated with chronic renal failure, liver failure, or haematological malignancy, as well as absence of headache and altered mental status.[60]Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001 Sep 1;33(5):690-9.
https://academic.oup.com/cid/article/33/5/690/468392
http://www.ncbi.nlm.nih.gov/pubmed/11477526?tool=bestpractice.com
Mortality rates due to cryptococcal meningitis remain high; 10-week mortality in a large US study was around 10%.[58]van der Horst C, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997 Jul 3;337(1):15-21.
http://www.nejm.org/doi/full/10.1056/NEJM199707033370103#t=article
http://www.ncbi.nlm.nih.gov/pubmed/9203426?tool=bestpractice.com
In less selected series, mortality has been higher, up to 26%. Reported 10-week mortality in studies from Africa and Asia has been 20% to 40% where amphotericin-B therapy has been available.[91]Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004 May 29;363(9423):1764-7.
http://www.ncbi.nlm.nih.gov/pubmed/15172774?tool=bestpractice.com
[121]Kambugu AD, Kamya M, Mayanja-Kizza H, et al. The high mortality of HIV associated Cryptococcal meningitis despite high dose amphotericin B therapy in Uganda. 41st Annual Meeting of The Infectious Diseases Society of America. San Diego, 2003. Abstract 629.[122]Imwidthaya P, Poungvarin N. Cryptococcosis in AIDS. Postgrad Med J. 2000 Feb;76(892):85-8.
http://www.ncbi.nlm.nih.gov/pubmed/10644384?tool=bestpractice.com
Cryptococcal meningitis continues to be one of the leading causes of death in HIV-infected patients, notably in Thailand, Uganda, Malawi, and South Africa, with an estimated mortality risk of 17% at 2 weeks and 34% at 10 weeks.[19]Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014 Mar;58(5):736-45.
https://academic.oup.com/cid/article/58/5/736/365633
http://www.ncbi.nlm.nih.gov/pubmed/24319084?tool=bestpractice.com
Chronic neuropsychiatric sequelae are common after cryptococcal meningitis and are associated with altered brain imaging parameters.[123]Lu CH, Chen HL, Chang WN, et al. Assessing the chronic neuropsychologic sequelae of human
immunodeficiency virus-negative cryptococcal meningitis by using diffusion tensor
imaging. AJNR Am J Neuroradiol. 2011 Aug;32(7):1333-9.
http://www.ajnr.org/content/32/7/1333.long
http://www.ncbi.nlm.nih.gov/pubmed/21596808?tool=bestpractice.com
Histoplasmal meningitis
Approximately 20% of patients fail initial therapy, and as many as 40% may relapse.[27]Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis. 2005 Mar 15;40(6):844-52.
https://academic.oup.com/cid/article/40/6/844/347054
http://www.ncbi.nlm.nih.gov/pubmed/15736018?tool=bestpractice.com
Coccidioidal meningitis
Despite advances in antifungal therapy, the morbidity and mortality associated with coccidioidal meningitis remains high, with mortality around 30%.[11]Johnson RH, Einstein HE. Coccidioidal meningitis. Clin Infect Dis. 2006 Jan 1;42(1):103-7.
https://academic.oup.com/cid/article/42/1/103/392976
http://www.ncbi.nlm.nih.gov/pubmed/16323099?tool=bestpractice.com
Because there is a high risk of relapse if therapy is stopped, treatment should be lifelong.[124]Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996 Feb 1;124(3):305-10.
http://www.ncbi.nlm.nih.gov/pubmed/8554225?tool=bestpractice.com
Candidal meningitis
Prognosis of candidal meningitis depends on the risk group, and mortality rates may vary from around 10% in neurosurgical patients to around 30% in HIV-infected patients.[42]Nguyen MH, Yu VL. Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin Infect Dis. 1995 Aug;21(2):323-7.
http://www.ncbi.nlm.nih.gov/pubmed/8562739?tool=bestpractice.com
[67]Casado JL, Quereda C, Oliva J, et al. Candidal meningitis in HIV-infected patients: analysis of 14 cases. Clin Infect Dis. 1997 Sep;25(3):673-6.
http://www.ncbi.nlm.nih.gov/pubmed/9314460?tool=bestpractice.com
Premature infants with candidal meningitis have a high rate of mortality and neurodevelopmental disabilities compared with matched controls: 60% versus 28%.[125]Lee BE, Cheung PY, Robinson JL, et al. Comparative study of mortality and morbidity in premature infants (birth weight <1,250 g) with candidaemia or candidal meningitis. Clin Infect Dis. 1998 Sep;27(3):559-65.
http://www.ncbi.nlm.nih.gov/pubmed/9770157?tool=bestpractice.com
Aspergillus meningitis
The diagnosis of Aspergillus meningitis is difficult, with an overall case fatality rate of nearly 70%; the prospect of a specific diagnosis in life is higher in immunocompetent patients.[53]Antinori S, Corbellino M, Meroni L, et al. Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis - case report and review of 92 cases. J Infect. 2013 Mar;66(3):218-38.
http://www.ncbi.nlm.nih.gov/pubmed/23178421?tool=bestpractice.com